3F80 Stock Chart & Stats
€1.63
€0.04(2.73%)
At close: 4:00 PM EDT
€1.63
€0.04(2.73%)
Day’s Range― - ―
52-Week Range€1.38 - €4.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€32.62M
Enterprise Value€147.98
Total Cash (Recent Filing)€186.77M
Total Debt (Recent Filing)€11.68M
Price to Earnings (P/E)―
Beta76.07
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.20
Shares Outstanding18,949,081
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.51
Revenue Forecast (FY)€7.12M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits interest and refinancing pressure, giving Q-linea greater financial flexibility while it develops its diagnostic platform. Positive equity provides some buffer, although continued losses could weaken that protection over time.
Reported Revenue GrowthThe reported growth rate indicates potential improvement in commercial traction and market adoption. If sustained through instrument placements and recurring cartridge usage, stronger revenue could improve operating leverage, though the current revenue base remains modest.
Recurring Consumables ModelConsumables linked to each patient test can create repeat revenue from the installed instrument base, supporting better revenue visibility than one-time equipment sales. This model can become more scalable as adoption expands across hospital laboratories.
Bears Say
Persistent Heavy LossesLarge losses across gross, operating, and net levels show that the current business has not reached a viable cost structure. Continued deficits can consume capital, constrain investment and make future funding more important to execution.
Substantial Cash BurnNegative operating and free cash flow indicate that operations are not yet self-funding and require continued financing or cash reserves. Persistent burn reduces flexibility and increases the risk of dilution or slower commercial investment.
Modest And Volatile Revenue BaseA small, volatile revenue base limits operating leverage and makes fixed development and commercialization costs harder to absorb. Until sales become more consistent, Q-linea may struggle to convert product adoption into durable margins and cash generation.
Q-linea AB News
3F80 FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was €1.38 and its highest was €4.24 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is €32.62M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Oct 30, 2026 which is in 50 days.
How were Q-linea AB’s earnings last quarter?
Q-linea AB released its earnings results on Jul 10, 2026. The company reported -€0.143 earnings per share for the quarter.
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Q-linea AB reported an EPS of -€0.143 in its last earnings report. Following the earnings report the stock price went down -8.039%.
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in DE:3F80
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.